Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Coffee drinkers had fewer repeat blood clots in a Norwegian study

14

Oct 2026

Coffee drinkers had fewer repeat blood clots in a Norwegian study

A Norwegian study involving 2,071 patients found that those who reported drinking 1 to 2 cups of coffee daily before their first venous thromboembolism had a 51% lower estimated risk of recurrence than non-drinkers. The association was strongest among patients whose initial blood clot was provoked, although the observational study could not establish that coffee consumption prevents recurrence.

Experts call for lifelong care after brain and spinal injuries

14

Oct 2026

Experts call for lifelong care after brain and spinal injuries

In a new paper published in The Lancet Neurology, "Reframing traumatic brain injury and spinal cord injury as chronic multisystem disorders: toward integrated, long-term care," international experts across institutions and disciplines propose a fundamental shift in how traumatic brain and spinal cord injuries in adults are understood and managed. Sandro Marini, MD, of the Mass General Brigham Neuroscience Institute, is a co-first author, and Saef Izzy, MD, also of the Neuroscience Institute, is one of the co-senior authors, and the primary corresponding author.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.